Atypical antipsychotic agents, which block postsynaptic dopamine and serotonin receptors, have advantages over traditional antipsychotic medications in the treatment of adults with schizophrenia and ...

Please provide your email address to receive an email when new articles are posted on . An oral, ultra-long-acting, extended-release risperidone capsule provided sustained therapeutic levels of ...

TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the publication of efficacy ...

Risperidone is a second-generation antipsychotic that lacks acute motor side effects at low doses (<6 mg/day), but above this level is associated with parkinsonism and akathesia. The literature ...

In a randomized, double-blind study, we evaluated patients with schizophrenia and a poor response to treatment with clozapine. The patients continued to take clozapine and were randomly assigned to ...

A final-stage clinical trial comparing a new long-acting, once-weekly pill to treat schizophrenia symptoms with the existing daily treatment has found that both produce comparable therapeutic effects.

Schizophrenia is a chronic and disabling disorder with a lifetime prevalence of approximately 1% (American Psychiatric Association 1994). It results in significant long-term functional handicap, ...

PARSIPPANY, N.J. & TEL AVIV, Israel & PARIS, February 25, 2025--(BUSINESS WIRE)--Regulatory News: Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), ...

Teva announces positive real-world outcomes for UZEDY® and TEV-'749 in schizophrenia treatment, highlighting improved adherence and reduced hospital visits. Teva Pharmaceuticals has announced positive ...

An investigational long-acting antipsychotic containing risperidone, known as TV-46000, was able to significantly delay time to relapse in patients with schizophrenia, according to the phase III RISE ...

The antipsychotic cariprazine (Reagila) is not only more effective than risperidone in treating patients with schizophrenia and persistent negative symptoms (PNS), it is also safe and effective for ...

UZEDY (risperidone) extended-release injectable suspension, for subcutaneous use, is indicated for the treatment of schizophrenia in adults. In clinical trials, UZEDY significantly reduced the risk of ...